Nanoparticle-Based Combinational Strategies for Overcoming the Blood-Brain Barrier and Blood-Tumor Barrier

References

• Abbott NJ, Ronnback L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. Nat Rev Neurosci. 2006;7(1):41–53. doi:10.1038/nrn1824
   PubMed Web of Science ®Google Scholar
• Kadry H, Noorani B, Cucullo L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17(1):69. doi:10.1186/s12987-020-00230-3
   PubMed Web of Science ®Google Scholar
• Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26–41. doi:10.1038/s41568-019-0205-x
   PubMed Web of Science ®Google Scholar
• Weiss N, Miller F, Cazaubon S, Couraud PO. The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta. 2009;1788(4):842–857. doi:10.1016/j.bbamem.2008.10.022
   PubMed Web of Science ®Google Scholar
• Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8(1):217. doi:10.1038/s41392-023-01481-w
   Web of Science ®Google Scholar
• Lim M, Xia Y, Bettegowda C, Weller M. Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol. 2018;15(7):422–442. doi:10.1038/s41571-018-0003-5
   PubMed Web of Science ®Google Scholar
• Rong L, Li N, Zhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022;41(1):142. doi:10.1186/s13046-022-02349-7
   PubMed Web of Science ®Google Scholar
• Cui J, Xu Y, Tu H, et al. Gather wisdom to overcome barriers: well-designed nano-drug delivery systems for treating gliomas. Acta Pharm Sin B. 2022;12(3):1100–1125. doi:10.1016/j.apsb.2021.08.013
   Web of Science ®Google Scholar
• Wadajkar AS, Dancy JG, Hersh DS, et al. Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(4):e1439.
   Web of Science ®Google Scholar
• Steeg PS. The blood–tumour barrier in cancer biology and therapy. Nat Rev Clin Oncol. 2021;18(11):696–714. doi:10.1038/s41571-021-00529-6
   PubMed Web of Science ®Google Scholar
• Guyon J, Chapouly C, Andrique L, Bikfalvi A, Daubon T. The normal and brain tumor vasculature: morphological and functional characteristics and therapeutic targeting. Front Physiol. 2021;12:622615. doi:10.3389/fphys.2021.622615
   Web of Science ®Google Scholar
• Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021;20(5):362–383. doi:10.1038/s41573-021-00139-y
   PubMed Web of Science ®Google Scholar
• Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8(6):1481–1493. doi:10.7150/thno.21254
   PubMed Web of Science ®Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• Duan L, Li X, Ji R, et al. Nanoparticle-based drug delivery systems: an inspiring therapeutic strategy for neurodegenerative diseases. Polymers. 2023;15(9):2196.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yue P, Peng Y, et al. Recent advances in drug delivery systems for targeting brain tumors. Drug Deliv. 2023;30(1):1–18. doi:10.1080/10717544.2022.2154409
   PubMed Web of Science ®Google Scholar
• Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano. 2013;7(11):9518–9525. doi:10.1021/nn405674m
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Kang MH, Qasim M, Kim JH. Nanoparticle-mediated combination therapy: two-in-one approach for cancer. Int J Mol Sci. 2018;19:3264.
   PubMed Web of Science ®Google Scholar
• Mottaghitalab F, Farokhi M, Fatahi Y, Atyabi F, Dinarvand R. New insights into designing hybrid nanoparticles for lung cancer: diagnosis and treatment. J Control Release. 2019;295:250–267. doi:10.1016/j.jconrel.2019.01.009
   PubMed Web of Science ®Google Scholar
• Cha GD, Kang T, Baik S, et al. Advances in drug delivery technology for the treatment of glioblastoma multiforme. J Control Release. 2020;328:350–367. doi:10.1016/j.jconrel.2020.09.002
   PubMed Web of Science ®Google Scholar
• Cha GD, Jung S, Choi SH, Kim DH. Local drug delivery strategies for glioblastoma treatment. Brain Tumor Res Treat. 2022;10(3):151–157. doi:10.14791/btrt.2022.0017
   Google Scholar
• Pandey N, Anastasiadis P, Carney CP, et al. Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment. Adv Drug Deliv Rev. 2022;188:114415.
   Web of Science ®Google Scholar
• Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16(7):896–913. doi:10.1093/neuonc/nou087
   PubMed Web of Science ®Google Scholar
• Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780. doi:10.1016/j.phrs.2021.105780
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13–25. doi:10.1016/j.nbd.2009.07.030
   PubMed Web of Science ®Google Scholar
• Mo F, Pellerino A, Soffietti R, Ruda R. Blood-brain barrier in brain tumors: biology and clinical relevance. Int J Mol Sci. 2021;22(23):12654.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, Cavenee WK; World Health O, International Agency for Research on C. WHO Classification of Tumours of the Central Nervous System. World Health Organization classification of tumours. International Agency For Research On Cancer; 2016:408.
   Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Aldoghachi AF, Aldoghachi AF, Breyne K, Ling KH, Cheah PS. Recent advances in the therapeutic strategies of glioblastoma multiforme. Neuroscience. 2022;491:240–270. doi:10.1016/j.neuroscience.2022.03.030
   PubMed Web of Science ®Google Scholar
• Armulik A, Genove G, Mae M, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:7323):557–U231. doi:10.1038/nature09522
   Web of Science ®Google Scholar
• Miller DS, Bauer B, Hartz AMS. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60(2):196–209. doi:10.1124/pr.107.07109
   PubMed Web of Science ®Google Scholar
• Tachibana K, Iwashita Y, Wakayama E, Nishino I, Nishikaji T, Kondoh M. Tight junction modulating bioprobes for drug delivery system to the brain: a review. Pharmaceutics. 2020;12(12):1236.
   Web of Science ®Google Scholar
• Rathi S, Griffith JI, Zhang W, et al. The influence of the blood-brain barrier in the treatment of brain tumours. J Intern Med. 2022;292(1):3–30. doi:10.1111/joim.13440
   Web of Science ®Google Scholar
• Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21(24):9739.
   PubMed Web of Science ®Google Scholar
• Ellert-Miklaszewska A, Poleszak K, Pasierbinska M, Kaminska B. Integrin signaling in glioma pathogenesis: from biology to therapy. Int J Mol Sci. 2020;21(3):888.
   PubMed Web of Science ®Google Scholar
• An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37(12):1561–1575. doi:10.1038/s41388-017-0045-7
   PubMed Web of Science ®Google Scholar
• Pearson JRD, Regad T. Targeting cellular pathways in glioblastoma multiforme. Signal Transduct Target Ther. 2017;2:17040. doi:10.1038/sigtrans.2017.40
   PubMed Web of Science ®Google Scholar
• Wen L, Tan Y, Dai S, et al. VEGF-mediated tight junctions pathological fenestration enhances doxorubicin-loaded glycolipid-like nanoparticles traversing BBB for glioblastoma-targeting therapy. Drug Deliv. 2017;24(1):1843–1855. doi:10.1080/10717544.2017.1386731
   PubMed Web of Science ®Google Scholar
• Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab. 2016;36(9):1481–1507. doi:10.1177/0271678X16655551
   PubMed Web of Science ®Google Scholar
• Ma J, Chen CC, Li M. Macrophages/microglia in the glioblastoma tumor microenvironment. Int J Mol Sci. 2021;22(11):5775.
   Web of Science ®Google Scholar
• Monteiro AR, Hill R, Pilkington GJ, Madureira PA. The role of hypoxia in glioblastoma invasion. Cells-Basel. 2017;6(4):45.
   PubMed Web of Science ®Google Scholar
• Blethen KE, Arsiwala TA, Fladeland RA, et al. Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. Neurooncol Adv. 2021;3(Suppl 5):v133–v143. doi:10.1093/noajnl/vdab123
   Google Scholar
• Khuri SF, Henderson WG, DePalma RG, et al. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg. 2005;242(3):326–341. doi:10.1097/01.sla.0000179621.33268.83
   PubMed Web of Science ®Google Scholar
• Chojak R, Kozba-Gosztyla M, Slychan K, et al. Impact of surgical resection of butterfly glioblastoma on survival: a meta-analysis based on comparative studies. Sci Rep. 2021;11(1):13934. doi:10.1038/s41598-021-93441-z
   Web of Science ®Google Scholar
• Ayloo S, Gu C. Transcytosis at the blood-brain barrier. Curr Opin Neurobiol. 2019;57:32–38. doi:10.1016/j.conb.2018.12.014
   PubMed Web of Science ®Google Scholar
• Li J, Zheng M, Shimoni O, et al. Development of novel therapeutics targeting the blood-brain barrier: from barrier to carrier. Adv Sci. 2021;8(16):e2101090. doi:10.1002/advs.202101090
   Web of Science ®Google Scholar
• Pulgar VM. Transcytosis to cross the blood brain barrier, new advancements and challenges. Front Neurosci. 2018;12:1019. doi:10.3389/fnins.2018.01019
   PubMed Web of Science ®Google Scholar
• Begley DJ. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004;10(12):1295–1312. doi:10.2174/1381612043384844
   PubMed Web of Science ®Google Scholar
• Gomez-Zepeda D, Taghi M, Scherrmann JM, Decleves X, Menet MC. ABC transporters at the blood-brain interfaces, their study models, and drug delivery implications in gliomas. Pharmaceutics. 2020;12(1):20.
   Web of Science ®Google Scholar
• Hong M. Biochemical studies on the structure-function relationship of major drug transporters in the ATP-binding cassette family and solute carrier family. Adv Drug Deliv Rev. 2017;116:3–20. doi:10.1016/j.addr.2016.06.003
   PubMed Web of Science ®Google Scholar
• Puris E, Fricker G, Gynther M. Targeting transporters for drug delivery to the brain: can we do better? Pharm Res. 2022;39(7):1415–1455. doi:10.1007/s11095-022-03241-x
   PubMed Web of Science ®Google Scholar
• Lu W. Adsorptive-mediated brain delivery systems. Curr Pharm Biotechnol. 2012;13(12):2340–2348. doi:10.2174/138920112803341851
   PubMed Web of Science ®Google Scholar
• Tuma P, Hubbard AL. Transcytosis: crossing cellular barriers. Physiol Rev. 2003;83(3):871–932. doi:10.1152/physrev.00001.2003
   PubMed Web of Science ®Google Scholar
• Habib S, Singh M. Angiopep-2-modified nanoparticles for brain-directed delivery of therapeutics: a review. Polymers. 2022;14(4):712.
   Web of Science ®Google Scholar
• Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117(2):333–345. doi:10.1111/j.1471-4159.2011.07208.x
   PubMed Web of Science ®Google Scholar
• Lalatsa A, Schatzlein AG, Uchegbu IF. Strategies to deliver peptide drugs to the brain. Mol Pharm. 2014;11(4):1081–1093. doi:10.1021/mp400680d
   PubMedGoogle Scholar
• Visser CC, Voorwinden LH, Crommelin DJ, Danhof M, de Boer AG. Characterization and modulation of the transferrin receptor on brain capillary endothelial cells. Pharm Res. 2004;21(5):761–769. doi:10.1023/b:pham.0000026425.69874.8e
   PubMed Web of Science ®Google Scholar
• Shawahna R, Uchida Y, Decleves X, et al. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm. 2011;8(4):1332–1341. doi:10.1021/mp200129p
   PubMed Web of Science ®Google Scholar
• Al-Majdoub ZM, Al Feteisi H, Achour B, et al. Proteomic quantification of human blood-brain barrier SLC and ABC transporters in healthy individuals and dementia patients. Mol Pharm. 2019;16(3):1220–1233. doi:10.1021/acs.molpharmaceut.8b01189
   Google Scholar
• Zhang W, Liu QY, Haqqani AS, et al. Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human. Fluids Barriers CNS. 2020;17(1):47. doi:10.1186/s12987-020-00209-0
   PubMed Web of Science ®Google Scholar
• Predescu SA, Predescu DN, Malik AB. Molecular determinants of endothelial transcytosis and their role in endothelial permeability. Am J Physiol-Lung C. 2007;293(4):L823–L842. doi:10.1152/ajplung.00436.2006
   PubMed Web of Science ®Google Scholar
• Talukder MJ, Takeuchi T, Harada E. Receptor-mediated transport of lactoferrin into the cerebrospinal fluid via plasma in young calves. J Vet Med Sci. 2003;65(9):957–964. doi:10.1292/jvms.65.957
   PubMed Web of Science ®Google Scholar
• Banks WA. The source of cerebral insulin. Eur J Pharmacol. 2004;490(1–3):5–12. doi:10.1016/j.ejphar.2004.02.040
   Web of Science ®Google Scholar
• Zlokovic BV, Skundric DS, Segal MB, Lipovac MN, Mackic JB, Davson H. A saturable mechanism for transport of immunoglobulin G across the blood-brain barrier of the Guinea pig. Exp Neurol. 1990;107(3):263–270. doi:10.1016/0014-4886(90)90144-h
   Web of Science ®Google Scholar
• Banks WA, Niehoff ML, Martin D, Farrell CL. Leptin transport across the blood-brain barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res. 2002;950(1–2):130–136. doi:10.1016/s0006-8993(02)03013-5
   Web of Science ®Google Scholar
• Herz J, Marschang P. Coaxing the LDL receptor family into the fold. Cell. 2003;112(3):289–292. doi:10.1016/S0092-8674(03)00073-4
   Web of Science ®Google Scholar
• Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv. 2005;2(2):299–309. doi:10.1517/17425247.2.2.299
   PubMedGoogle Scholar
• Pan W, Kastin AJ. TNFα transport across the blood-brain barrier is abolished in receptor knockout mice. Exp Neurol. 2002;174(2):193–200. doi:10.1006/exnr.2002.7871
   PubMed Web of Science ®Google Scholar
• Kamalinia G, Khodagholi F, Shaerzadeh F, et al. Cationic albumin-conjugated chelating agent as a novel brain drug delivery system in neurodegeneration. Chem Biol Drug Des. 2015;86(5):1203–1214. doi:10.1111/cbdd.12586
   Web of Science ®Google Scholar
• Drin G, Cottin S, Blanc E, Rees AR, Temsamani J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem. 2003;278(33):31192–31201. doi:10.1074/jbc.M303938200
   PubMed Web of Science ®Google Scholar
• Ding S, Khan AI, Cai X, et al. Overcoming blood-brain barrier transport: advances in nanoparticle-based drug delivery strategies. Mater Today. 2020;37:112–125. doi:10.1016/j.mattod.2020.02.001
   Web of Science ®Google Scholar
• Li YJ, Wu JY, Liu J, et al. From blood to brain: blood cell-based biomimetic drug delivery systems. Drug Deliv. 2021;28(1):1214–1225. doi:10.1080/10717544.2021.1937384
   PubMed Web of Science ®Google Scholar
• Le QV, Lee J, Lee H, Shim G, Oh YK. Cell membrane-derived vesicles for delivery of therapeutic agents. Acta Pharm Sin B. 2021;11(8):2096–2113. doi:10.1016/j.apsb.2021.01.020
   PubMed Web of Science ®Google Scholar
• Ruiz-Garcia H, Alvarado-Estrada K, Krishnan S, Quinones-Hinojosa A, Trifiletti DM. Nanoparticles for stem cell therapy bioengineering in glioma. Front Bioeng Biotechnol. 2020;8:558375. doi:10.3389/fbioe.2020.558375
   PubMed Web of Science ®Google Scholar
• Guo Y, Hu D, Lian L, et al. Stem cell-derived extracellular vesicles: a promising nano delivery platform to the brain? Stem Cell Rev Rep. 2023;19(2):285–308. doi:10.1007/s12015-022-10455-4
   Web of Science ®Google Scholar
• Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23(4):236–250. doi:10.1038/s41577-022-00763-8
   PubMed Web of Science ®Google Scholar
• Sedgwick AJ, Ghazanfari N, Constantinescu P, Mantamadiotis T, Barrow AD. The role of NK cells and innate lymphoid cells in brain cancer. Front Immunol. 2020;11:1549. doi:10.3389/fimmu.2020.01549
   Google Scholar
• Wei J, Chen P, Gupta P, et al. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020;22(2):180–194. doi:10.1093/neuonc/noz212
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799–820. doi:10.1038/s41573-022-00520-5
   PubMed Web of Science ®Google Scholar
• Buonfiglioli A, Hambardzumyan D. Macrophages and microglia: the cerberus of glioblastoma. Acta Neuropathol Commun. 2021;9(1):54. doi:10.1186/s40478-021-01156-z
   PubMed Web of Science ®Google Scholar
• Ou A, Wang Y, Zhang J, Huang Y. Living cells and cell-derived vesicles: a trojan horse technique for brain delivery. Pharmaceutics. 2023;15(4):1257.
   Web of Science ®Google Scholar
• Wang C, Li K, Li T, et al. Monocyte-mediated chemotherapy drug delivery in glioblastoma. Nanomedicine (Lond). 2018;13(2):157–178. doi:10.2217/nnm-2017-0266
   PubMed Web of Science ®Google Scholar
• Pang L, Zhu Y, Qin J, Zhao W, Wang J. Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy. Drug Deliv. 2018;25(1):1922–1931. doi:10.1080/10717544.2018.1502839
   PubMed Web of Science ®Google Scholar
• Choi A, Javius-Jones K, Hong S, Park H. Cell-based drug delivery systems with innate homing capability as a novel nanocarrier platform. Int J Nanomed. 2023;18:509–525. doi:10.2147/IJN.S394389
   PubMed Web of Science ®Google Scholar
• Rosales C. Neutrophil: a cell with many roles in inflammation or several cell types? Front Physiol. 2018;9:324475.
   Web of Science ®Google Scholar
• Malech HL, DeLeo FR, Quinn MT. The Role of Neutrophils in the Immune System: an Overview. Methods Mol Biol. 2020;2087:3–10. doi:10.1007/978-1-0716-0154-9_1
   Google Scholar
• Wang HJ, Zang J, Zhao ZH, Zhang Q, Chen SJ. The advances of neutrophil-derived effective drug delivery systems: a key review of managing tumors and inflammation. Int J Nanomed. 2021;16:7663–7681. doi:10.2147/Ijn.S328705
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang HG, Zhang QX, Tao H. Research progress of neutrophil-mediated drug delivery strategies for inflammation-related disease. Pharmaceutics. 2023;15(7):1881.
   Web of Science ®Google Scholar
• Wu M, Zhang H, Tie C, et al. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma. Nat Commun. 2018;9(1):4777. doi:10.1038/s41467-018-07250-6
   PubMedGoogle Scholar
• Fang Y, Jiang Y, Zou Y, et al. Targeted glioma chemotherapy by cyclic RGD peptide-functionalized reversibly core-crosslinked multifunctional poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles. Acta Biomater. 2017;50:396–406. doi:10.1016/j.actbio.2017.01.007
   PubMed Web of Science ®Google Scholar
• Jin SJ, Sun YP, Liang X, et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduction Tar. 2022;7(1). doi:10.1038/s41392-021-00868-x
   Web of Science ®Google Scholar
• Kumari M, Acharya A, Krishnamurthy PT. Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics. Beilstein J Nanotechnol. 2023;14:912–926. doi:10.3762/bjnano.14.75
   PubMed Web of Science ®Google Scholar
• Fu ZW, Li SJ, Han SF, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduction Tar. 2022;7(1):93.
   PubMed Web of Science ®Google Scholar
• Bajracharya R, Caruso AC, Vella LJ, Nisbet RM. Current and emerging strategies for enhancing antibody delivery to the brain. Pharmaceutics. 2021;13(12):2014.
   Web of Science ®Google Scholar
• Teixeira MI, Lopes CM, Amaral MH, Costa PC. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces. 2023;221:112999. doi:10.1016/j.colsurfb.2022.112999
   PubMed Web of Science ®Google Scholar
• Ramalho MJ, Loureiro JA, Coelho MAN, Pereira MC. Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma. Pharmaceutics. 2022;14(2):279.
   PubMed Web of Science ®Google Scholar
• Koneru T, McCord E, Pawar S, Tatiparti K, Sau S, Iyer AK. Transferrin: biology and use in receptor-targeted nanotherapy of gliomas. ACS Omega. 2021;6(13):8727–8733. doi:10.1021/acsomega.0c05848
   PubMed Web of Science ®Google Scholar
• Paris-Robidas S, Emond V, Tremblay C, Soulet D, Calon F. In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor. Mol Pharmacol. 2011;80(1):32–39. doi:10.1124/mol.111.071027
   PubMed Web of Science ®Google Scholar
• Kang Y-S, Jung H-J, Oh J-S, Song D-Y. Use of PEGylated immunoliposomes to deliver dopamine across the blood–brain barrier in a rat model of parkinson’s disease. CNS Neurosci Ther. 2016;22(10):817–823. doi:10.1111/cns.12580
   PubMed Web of Science ®Google Scholar
• Gomes MJ, Kennedy PJ, Martins S, Sarmento B. Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood–brain barrier. Nanomedicine. 2017;12(12):1385–1399. doi:10.2217/nnm-2017-0023
   PubMed Web of Science ®Google Scholar
• Lee YK, Choi E-J, Webster TJ, Kim S-H, Khang D. Effect of the protein Corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int J Nanomed. 2015;10:97–113. doi:10.2147/IJN.S72998
   PubMed Web of Science ®Google Scholar
• Lima T, Bernfur K, Vilanova M, Cedervall T. Understanding the lipid and protein corona formation on different sized polymeric nanoparticles. Sci Rep. 2020;10(1):1129. doi:10.1038/s41598-020-57943-6
   PubMed Web of Science ®Google Scholar
• Marei HE. Multimodal targeting of glioma with functionalized nanoparticles. Cancer Cell Int. 2022;22(1):265. doi:10.1186/s12935-022-02687-8
   Web of Science ®Google Scholar
• Lu R-M, Hwang Y-C, Liu I-J, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. doi:10.1186/s12929-019-0592-z
   PubMed Web of Science ®Google Scholar
• Fam SY, Chee CF, Yong CY, Ho KL, Mariatulqabtiah AR, Tan WS. Stealth coating of nanoparticles in drug-delivery systems. Nanomaterials. 2020;10(4):787. doi:10.3390/nano10040787
   Web of Science ®Google Scholar
• Kong J, Zou R, Law G-L, Wang Y. Biomimetic multifunctional persistent luminescence nanoprobes for long-term near-infrared imaging and therapy of cerebral and cerebellar gliomas. Sci Adv. 2022;8(10):eabm7077. doi:10.1126/sciadv.abm7077
   PubMed Web of Science ®Google Scholar
• Cui YX, Sun JJ, Hao WY, et al. Dual-target peptide-modified erythrocyte membrane-enveloped PLGA nanoparticles for the treatment of glioma. Front Oncol. 2020;10. doi:10.3389/fonc.2020.563938
   Web of Science ®Google Scholar
• Allami P, Heidari A, Rezaei N. The role of cell membrane-coated nanoparticles as a novel treatment approach in glioblastoma. Front Mol Biosci. 2023;9:1083645.
   Web of Science ®Google Scholar
• Sharif S, Ghahremani MH, Soleimani M. Delivery of exogenous miR-124 to glioblastoma multiform cells by wharton’s jelly mesenchymal stem cells decreases cell proliferation and migration, and confers chemosensitivity. Stem Cell Rev Rep. 2018;14(2):236–246. doi:10.1007/s12015-017-9788-3
   Web of Science ®Google Scholar
• Zhang C, Song J, Lou L, et al. Doxorubicin-loaded nanoparticle coated with endothelial cells-derived exosomes for immunogenic chemotherapy of glioblastoma. Bioeng Transl Med. 2021;6(3):e10203. doi:10.1002/btm2.10203
   PubMed Web of Science ®Google Scholar
• Zhong L, Wang J, Wang P, et al. Neural stem cell-derived exosomes and regeneration: cell-free therapeutic strategies for traumatic brain injury. Stem Cell Res Ther. 2023;14(1):198. doi:10.1186/s13287-023-03409-1
   Web of Science ®Google Scholar
• Lee H, Bae K, Baek AR, et al. Glioblastoma-Derived Exosomes as Nanopharmaceutics for Improved Glioma Treatment. Pharmaceutics. 2022;14(5):1002.
   Web of Science ®Google Scholar
• Karami Fath M, Azami J, Masoudi A, et al. Exosome-based strategies for diagnosis and therapy of glioma cancer. Cancer Cell Int. 2022;22(1):262. doi:10.1186/s12935-022-02642-7
   Web of Science ®Google Scholar
• Li J, Wei Y, Zhang C, et al. Cell-membrane-coated nanoparticles for targeted drug delivery to the brain for the treatment of neurological diseases. Pharmaceutics. 2023;15(2):621.
   PubMed Web of Science ®Google Scholar
• Burgess A, Shah K, Hough O, Hynynen K. Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev Neurother. 2015;15(5):477–491. doi:10.1586/14737175.2015.1028369
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Liu M, Ojha T, Storm G, Kiessling F, Lammers T. Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. Drug Discov Today Technol. 2016;20:41–48. doi:10.1016/j.ddtec.2016.07.007
   PubMedGoogle Scholar
• Zhang S, Zhang S, Luo S, et al. Ultrasound-assisted brain delivery of nanomedicines for brain tumor therapy: advance and prospect. J Nanobiotechnology. 2022;20(1):287. doi:10.1186/s12951-022-01464-z
   PubMed Web of Science ®Google Scholar
• Barzegar-Fallah A, Gandhi K, Rizwan SB, Slatter TL, Reynolds JNJ. Harnessing ultrasound for targeting drug delivery to the brain and breaching the blood-brain tumour barrier. Pharmaceutics. 2022;14:2231.
   Web of Science ®Google Scholar
• Martinez P, Nault G, Steiner J, et al. MRI-guided focused ultrasound blood-brain barrier opening increases drug delivery and efficacy in a diffuse midline glioma mouse model. Neurooncol Adv. 2023;5(1):vdad111. doi:10.1093/noajnl/vdad111
   Google Scholar
• Phillips LC, Dhanaliwala AH, Klibanov AL, Hossack JA, Wamhoff BR. Focused ultrasound-mediated drug delivery from microbubbles reduces drug dose necessary for therapeutic effect on neointima formation--brief report. Arterioscler Thromb Vasc Biol. 2011;31(12):2853–2855. doi:10.1161/ATVBAHA.111.238170
   Web of Science ®Google Scholar
• Wu SY, Sanchez CS, Samiotaki G, Buch A, Ferrera VP, Konofagou EE. Characterizing focused-ultrasound mediated drug delivery to the heterogeneous primate brain in vivo with acoustic monitoring. Sci Rep. 2016;6:37094. doi:10.1038/srep37094
   PubMed Web of Science ®Google Scholar
• Arsiwala TA, Sprowls SA, Blethen KE, et al. Ultrasound-mediated disruption of the blood tumor barrier for improved therapeutic delivery. Neoplasia. 2021;23(7):676–691. doi:10.1016/j.neo.2021.04.005
   PubMed Web of Science ®Google Scholar
• Brighi C, Salimova E, de Veer M, Puttick S, Egan G. Translation of focused ultrasound for blood-brain barrier opening in glioma. J Control Release. 2022;345:443–463. doi:10.1016/j.jconrel.2022.03.035
   PubMed Web of Science ®Google Scholar
• Wang S, Chen Y, Guo J, Huang Q. Liposomes for tumor targeted therapy: a review. Int J Mol Sci. 2023;24(3):2643.
   Web of Science ®Google Scholar
• Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles horizontal line from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–17015. doi:10.1021/acsnano.1c04996
   PubMed Web of Science ®Google Scholar
• Kim YS, Ko MJ, Moon H, et al. Ultrasound-responsive liposomes for targeted drug delivery combined with focused ultrasound. Pharmaceutics. 2022;14(7):1314.
   Web of Science ®Google Scholar
• Papachristodoulou A, Signorell RD, Werner B, et al. Chemotherapy sensitization of glioblastoma by focused ultrasound-mediated delivery of therapeutic liposomes. J Control Release. 2019;295:130–139. doi:10.1016/j.jconrel.2018.12.009
   PubMed Web of Science ®Google Scholar
• Zhang X, Hu J, Zhao G, et al. PEGylated PLGA-based phase shift nanodroplets combined with focused ultrasound for blood brain barrier opening in rats. Oncotarget. 2017;8(24):38927–38936. doi:10.18632/oncotarget.17155
   Google Scholar
• Wang F, Dong L, Liang SM, et al. Ultrasound-triggered drug delivery for glioma therapy through gambogic acid-loaded nanobubble-microbubble complexes. Biomed Pharmacother. 2022;150:113042.
   PubMed Web of Science ®Google Scholar
• Hersh AM, Bhimreddy M, Weber-Levine C, et al. Applications of focused ultrasound for the treatment of glioblastoma: a new frontier. Cancers. 2022;14(19):4920.
   Web of Science ®Google Scholar
• Mody VV, Cox A, Shah S, Singh A, Bevins W, Parihar H. Magnetic nanoparticle drug delivery systems for targeting tumor. Appl Nanosci. 2014;4(4):385–392. doi:10.1007/s13204-013-0216-y
   Web of Science ®Google Scholar
• Yang HW, Hua MY, Liu HL, Huang CY, Wei KC. Potential of magnetic nanoparticles for targeted drug delivery. Nanotechnol Sci Appl. 2012;5:73–86. doi:10.2147/NSA.S35506
   PubMedGoogle Scholar
• Huang J, Li Y, Orza A, et al. Magnetic nanoparticle facilitated drug delivery for cancer therapy with targeted and image-guided approaches. Adv Funct Mater. 2016;26(22):3818–3836. doi:10.1002/adfm.201504185
   PubMed Web of Science ®Google Scholar
• Spoiala A, Ilie CI, Motelica L, et al. Smart magnetic drug delivery systems for the treatment of cancer. Nanomaterials-Basel. 2023;13(5):876.
   Web of Science ®Google Scholar
• Zeng S, Tang Q, Xiao M, et al. Cell membrane-coated nanomaterials for cancer therapy. Mater Today Bio. 2023;20:100633. doi:10.1016/j.mtbio.2023.100633
   PubMedGoogle Scholar
• Wahajuddin Arora S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomed. 2012;7:3445–3471. doi:10.2147/Ijn.S30320
   PubMed Web of Science ®Google Scholar
• Marino A, Camponovo A, Degl’Innocenti A, et al. Multifunctional temozolomide-loaded lipid superparamagnetic nanovectors: dual targeting and disintegration of glioblastoma spheroids by synergic chemotherapy and hyperthermia treatment. Nanoscale. 2019;11(44):21227–21248. doi:10.1039/c9nr07976a
   PubMed Web of Science ®Google Scholar
• Wlodarczyk A, Gorgon S, Radon A, Bajdak-Rusinek K. Magnetite nanoparticles in magnetic hyperthermia and cancer therapies: challenges and perspectives. Nanomaterials. 2022;12(11):1807.
   Web of Science ®Google Scholar
• Chang D, Lim M, Goos J, et al. Biologically targeted magnetic hyperthermia: potential and Limitations. Front Pharmacol. 2018;9:831. doi:10.3389/fphar.2018.00831
   PubMed Web of Science ®Google Scholar
• Michael JS, Lee BS, Zhang MQ, Yu JS. Nanotechnology for treatment of glioblastoma multiforme. J Transl Intern Med. 2018;6(3):128–133. doi:10.2478/jtim-2018-0025
   PubMed Web of Science ®Google Scholar
• Wankhede M, Bouras A, Kaluzova M, Hadjipanayis CG. Magnetic nanoparticles: an emerging technology for malignant brain tumor imaging and therapy. Expert Rev Clin Pharmacol. 2012;5(2):173–186. doi:10.1586/ecp.12.1
   PubMed Web of Science ®Google Scholar
• Henkin RI. Intranasal delivery to the brain. Nat Biotechnol. 2011;29(6):480. doi:10.1038/nbt.1866
   PubMed Web of Science ®Google Scholar
• Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9(Suppl 3):S5. doi:10.1186/1471-2202-9-S3-S5
   PubMed Web of Science ®Google Scholar
• Jeong SH, Jang JH, Lee YB. Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors. J Pharm Invest. 2023;53(1):119–152. doi:10.1007/s40005-022-00589-5
   Web of Science ®Google Scholar
• Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today. 2022;29:101631.
   Web of Science ®Google Scholar
• Lee D, Minko T. Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics. 2021;13(12):2049.
   PubMed Web of Science ®Google Scholar
• Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44–52. doi:10.1016/j.lfs.2017.12.025
   PubMed Web of Science ®Google Scholar
• Shah P, Sarolia J, Vyas B, Wagh P, Ankur K, Kumar MA. PLGA nanoparticles for nose to brain delivery of clonazepam: formulation, optimization by 32 factorial design, in vitro and in vivo evaluation. Curr Drug Deliv. 2021;18(6):805–824. doi:10.2174/1567201817666200708115627
   PubMed Web of Science ®Google Scholar
• Xinchen Y, Jing T, Jiaoqiong G. Lipid-based nanoparticles via nose-to-brain delivery: a mini review. Front Cell Dev Biol. 2023;11:1214450. doi:10.3389/fcell.2023.1214450
   Web of Science ®Google Scholar
• Hong SS, Oh KT, Choi HG, Lim SJ. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics. 2019;11(10):540.
   PubMed Web of Science ®Google Scholar
• Kim KR, Lee AS, Kim SM, Heo HR, Kim CS. Virus-like nanoparticles as a theranostic platform for cancer. Front Bioeng Biotechnol. 2022;10:1106767. doi:10.3389/fbioe.2022.1106767
   Web of Science ®Google Scholar
• Mohsen MO, Bachmann MF. Virus-like particle vaccinology, from bench to bedside. Cell Mol Immunol. 2022;19(9):993–1011. doi:10.1038/s41423-022-00897-8
   PubMed Web of Science ®Google Scholar
• Nooraei S, Bahrulolum H, Hoseini ZS, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology. 2021;19(1):59. doi:10.1186/s12951-021-00806-7
   PubMed Web of Science ®Google Scholar
• Ikwuagwu B, Tullman-Ercek D. Virus-like particles for drug delivery: a review of methods and applications. Curr Opin Biotechnol. 2022;78:102785. doi:10.1016/j.copbio.2022.102785
   Web of Science ®Google Scholar
• Zhang L, Zhou L, Bao L, et al. SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. 2021;6(1):337. doi:10.1038/s41392-021-00719-9
   PubMed Web of Science ®Google Scholar
• Kim KS. Investigating bacterial penetration of the blood-brain barrier for the pathogenesis, prevention, and therapy of bacterial meningitis. ACS Infect Dis. 2020;6(1):34–42. doi:10.1021/acsinfecdis.9b00319
   Web of Science ®Google Scholar
• Ye D, Zimmermann T, Demina V, et al. Trafficking of JC virus-like particles across the blood-brain barrier. Nanoscale Adv. 2021;3(9):2488–2500. doi:10.1039/d0na00879f
   Web of Science ®Google Scholar
• Nowak I, Madej M, Secemska J, Sarna R, Strzalka-Mrozik B. Virus-based biological systems as next-generation carriers for the therapy of central nervous system diseases. Pharmaceutics. 2023;15(7):1931.
   Web of Science ®Google Scholar
• Chen YL, Bao CJ, Duan JL, Xie Y, Lu WL. Overcoming biological barriers by virus-like drug particles for drug delivery. Adv Drug Deliv Rev. 2023;203:115134. doi:10.1016/j.addr.2023.115134
   Web of Science ®Google Scholar
• Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. Saudi Pharm J. 2018;26(1):64–70. doi:10.1016/j.jsps.2017.10.012
   PubMed Web of Science ®Google Scholar
• Mehta N, Lyon JG, Patil K, Mokarram N, Kim C, Bellamkonda RV. Bacterial carriers for glioblastoma therapy. Mol Ther Oncolytics. 2017;4:1–17. doi:10.1016/j.omto.2016.12.003
   PubMed Web of Science ®Google Scholar
• Sun R, Liu M, Lu J, et al. Bacteria loaded with glucose polymer and photosensitive ICG silicon-nanoparticles for glioblastoma photothermal immunotherapy. Nat Commun. 2022;13(1):5127. doi:10.1038/s41467-022-32837-5
   Web of Science ®Google Scholar
• Pardridge WM. Drug transport across the blood-brain barrier. J Cerebr Blood F Met. 2012;32(11):1959–1972. doi:10.1038/jcbfm.2012.126
   PubMed Web of Science ®Google Scholar
• Pardridge WM. CSF, blood-brain barrier, and brain drug delivery. Expert Opin Drug Deliv. 2016;13(7):963–975. doi:10.1517/17425247.2016.1171315
   PubMed Web of Science ®Google Scholar
• Kucuksayan E, Bozkurt F, Yilmaz MT, Sircan-Kucuksayan A, Hanikoglu A, Ozben T. A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers. Sci Rep-Uk. 2021;11(1):13027.
   Web of Science ®Google Scholar
• Fang RH, Gao W, Zhang L. Targeting drugs to tumours using cell membrane-coated nanoparticles. Nat Rev Clin Oncol. 2023;20(1):33–48. doi:10.1038/s41571-022-00699-x
   PubMed Web of Science ®Google Scholar
• Zhao M, van Straten D, Broekman MLD, Preat V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10(3):1355–1372. doi:10.7150/thno.38147
   PubMed Web of Science ®Google Scholar
• Gupta S, Smith TR, Broekman ML. Ethical considerations of neuro-oncology trial design in the era of precision medicine. J Neurooncol. 2017;134(1):1–7. doi:10.1007/s11060-017-2502-0
   Web of Science ®Google Scholar
• Alghamdi MA, Fallica AN, Virzi N, Kesharwani P, Pittala V, Greish K. The promise of nanotechnology in personalized medicine. J Pers Med. 2022;12(5):673.
   Web of Science ®Google Scholar
• Gil PR. Nanotechnology opens the landscape of personalized medicine. Curr Med Chem. 2018;25(35):4552. doi:10.2174/092986732535181026145729
   Web of Science ®Google Scholar
• Chehelgerdi M, Chehelgerdi M, Allela OQB, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22(1):169. doi:10.1186/s12943-023-01865-0
   PubMed Web of Science ®Google Scholar